News & Media Press releases & statements Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Apply filter Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Apply filter Year All Years 2023 2022 2021 2020 2019 2018 2017 2016 2015 Category All categories Type - Statement - Press release Topic - Corporate and finance - Global health - Partnerships Research area - COVID-19 - Ebola - RSV - Seasonal influenza Uncategorized Keywords Apply filter Advanced Search Search Search Headlines Only Type All Statement Press release Topic All Corporate and finance Global health Partnerships Research area All COVID-19 Ebola RSV Seasonal influenza From To Asset Types Photos Video Audio Documents Events Standard Jun 5, 2023 Corporate and finance Novavax Announces Agreement with Bill & Melinda Gates Medical Research Institute to Include Matrix-M™ Adjuvant as Potential Component in Vaccine Research Download Jun 1, 2023 Novavax to Participate in the Jefferies Global Healthcare Conference Download May 26, 2023 COVID-19 Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU Download May 12, 2023 COVID-19 Access to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore Download May 9, 2023 Corporate and finance Novavax Reports First Quarter 2023 Financial Results and Operational Highlights Download May 9, 2023 COVID-19Seasonal influenza Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses Download May 4, 2023 Novavax to Participate in the BofA Securities 2023 Health Care Conference Download May 2, 2023 Corporate and finance Novavax to Host Conference Call to Discuss First Quarter 2023 Financial Results and Operational Highlights on May 9, 2023 Download Apr 27, 2023 Statement PREVENT-19 Adolescent Data Published in the Journal of the American Medical Association Network Open Download Apr 17, 2023 Statement Novavax’s Novel Matrix-M™ Adjuvant Technology is Key Component of Oxford Malaria Vaccine Download Apr 4, 2023 COVID-19Seasonal influenza Novavax Grows Presence at World Vaccine Congress 2023 and 33rd European Congress of Clinical Microbiology & Infectious Diseases Download Mar 6, 2023 Novavax to Participate in TD Cowen's 43rd Annual Health Care Conference Download Mar 2, 2023 Corporate and finance Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4) Download Feb 28, 2023 Corporate and finance Novavax Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights Download Feb 21, 2023 Corporate and finance Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 28, 2023 Download Feb 13, 2023 COVID-19 U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine Download Jan 27, 2023 StatementCOVID-19 Novavax Announces Plan to Deliver Updated Protein-based Vaccine Consistent with FDA Recommendations for 2023/2024 Vaccination Season at VRBPAC Meeting Download Jan 25, 2023 Corporate and finance Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4) Download Jan 18, 2023 COVID-19 Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster Download Jan 9, 2023 Corporate and finance Novavax Names John C. Jacobs as New President & Chief Executive Officer Download Jan 9, 2023 Statement Novavax to Participate in the 41st Annual J.P. Morgan Healthcare Conference Download Jan 5, 2023 Spanish, Italian and French Health Authorities Expand Recommendations for Use of Novavax COVID-19 Vaccine Download Dec 30, 2022 COVID-19Seasonal influenza Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates Download Dec 28, 2022 Corporate and finance Novavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common Stock Download Dec 16, 2022 StatementGlobal healthCOVID-19 German Health Authority Expands Recommendation for Use of Novavax COVID-19 Vaccine as a Booster Download Show 5102550100 per page«123456789…19»